-
Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Key Trial Highlights Total 11 sites now active in US 5 European…
-
ImmuPharma Invited to Open an Additional Site in Mauritius
Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…
-
ImmuPharma Invited to Open an Additional Site in Mauritius
Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…
-
Northland Capital Appointed as Joint Broker
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces the appointment of Northland Capital Partners as joint broker to the Company, alongside Panmure Gordon with immediate effect.
-
Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. This event, to…
-
First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the first European sites opened…
-
Notification of Major Interest by Alto Invest to 4.15%
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming that it has increased its holding to 5,053,548 million Ordinary Shares in the capital of the Company. This represents 4.15% of ImmuPharma’s total voting…
-
Notification of Major Interest by Alto Invest
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming its holding in ImmuPharma of 4,870,367 million Ordinary Shares in the capital of the Company, representing 3.99% of the Company’s total voting rights, crossing…
-
PRELIMINARY RESULTS for the year ended 31 December 2015
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary results for the year ended 31 December 2015. Key Highlights: Lupuzor™ Pivotal Phase III clinical trial for Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, is progressing, in conjunction with Simbec-Orion,…
-
Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders. The 2015 Annual Report can be downloaded here The Company’s Annual General Meeting will be held on Thursday 26 May 2016 at…
